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Abstract  
Background: Pan-resistant Acinetobacter infection has emerged as an important nosocomial pathogen in our inpatient neonates over the past 
few years. 
Methodology: We performed a retrospective chart review during a five-year period (July 2003 – June 2008) of all neonates hospitalized in 
our neonatal intensive care unit (NICU) who developed Acinetobacter infection to identify mortality-associated risk factors in Acinetobacter 
neonatal infection.  
Results: During the five-year study period, 122 cultures from 78 neonates grew Acinetobacter. Source sites of positive culture were in the 
following descending order: blood (n = 57), trachea (n = 55), tissue/wound/body fluids (n = 4), eye (n = 4), urine (n = 1), and cerebrospinal 
fluid (n = 1). Twenty-four (31%) patients had Acinetobacter isolated from more than one site. At the time of admission the mean age was 
2.08 ± 4 days and mean weight was 1.77 ± 0.88 kg; 75% were premature. Pan-resistance (87/122; sensitive only to Polymyxin) was present 
in 71% of Acinetobacter isolates. Crude mortality rate of this cohort was 47%, while 70% of patients died within four days after positive 
Acinetobacter culture. We identified weight of less than 1 kg on admission (p 0.06, adjusted Odds Ratio (AOR) 1.53), gestational age 28 
weeks or less (p 0.011, AOR 2.88), poor perfusion (p 0.007, AOR 2.4), thrombocytopenia (p 0.01; AOR 1.6) and metabolic acidosis (p 0.01; 
AOR 1.67) as predictors associated with poor outcome.    
Conclusion: Pan-resistant Acinetobacter infection is exceedingly fatal in newborns, particularly in premature and very low-birth weight 
neonates. Rational antibiotic use and vigilant infection control in NICUs are key to controlling multi-drug resistant Acinetobacter infection 
and improving clinical outcome.  
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Introduction 
Acinetobacter has emerged as an important 
nosocomial organism causing infectious outbreaks in 
critically ill patients leading to high mortality and 
morbidity [1,2]. It has become one of the top seven 
pathogens threatening the current health care delivery 
system, particularly the intensive care setting [3]. 
Because of its remarkable ability to colonize patients 
and the nosocomial environment, it causes hospital 
outbreaks due to cross-transmission between patients 
[4]. It is associated with ventilator acquired 
pneumonia (VAP), blood stream infection (BSI), 
urinary tract infection (UTI) and central  nervous 
system (CNS) infection in neonates.  
Acinetobacter spp. has become one of the 
greatest threats for our current health care system 
because of its resistance to most known drugs. It has 
emerged as a multi-drug resistant (MDR) organism 
moving towards pan-resistance [5].  In general 
Acinetobacter is considered as an organism with low 
virulence but issues such as critical 
illness/immunocompromised status, prematurity, low 
birth weight, endotracheal intubation, parenteral 
nutrition, intravascular catheterization and broad 
spectrum antibiotic therapy are known risk factors for 
Acinetobacter spp. septicemia [6].  The crude 
mortality (at any age) for Acinetobacter spp. ranges 
from 23 - 73% [7]. The association between MDR 
Acinetobacter (MDRAB) and mortality is 
increasingly established in literature; this is why it 
has become one of the most studied and reported 
organisms in health care institutes and also in public 
health [2].  There is a dearth of literature identifying 
factors related to high mortality in neonates with 
Acinetobacter infection requiring high-level care. We 
therefore attempt to identify important risk factors 
associated with increased mortality in neonates with 
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Acinetobacter spp. infection in our intensive care 
unit. 
 
Materials and methods 
Study Population and Identification 
We performed a retrospective chart review of all 
neonates with discharge diagnosis of Acinetobacter 
infection from the NICU at Aga Khan University 
Hospital, Karachi, from July 2003 to June 2008. As 
there is no International Classification of Disease 
(ICD – 2008) available for Acinetobacter spp. 
infection, we identified the cases by using two 
mechanisms: filtering other Gram-negative organism-
related infections in discharged patients, and  using 
the log book of our neonatal intensive care unit 
(NICU) which records all discharge diagnoses.  
Upon filtering, we identified 187 cases, which 
were narrowed down to 78 cases with Acinetobacter 
infection only on file review. These 78 cases were 
later included in the final analysis. We enrolled cases 
who acquired Acinetobacter infection after 48 hours 
in the NICU. Those with pre-existing culture-proven 
Acinetobacter infection at the time of admission in 
NICU or incomplete medical records were excluded 
from the study.   
 
Study Setting 
We have a 13-bed, level III NICU (with 12 
ventilators) providing all neonatal services except 
Extra Corporeal Membrane Oxygenation (ECMO) 
and hemodialysis. We provide care to more than 450 
neonates annually. Premature births make up 
approximately 15-20% of cases, while 15% of the 
premature were extremely low birth weight. Our 
NICU is divided into four levels of care: level 1, six 
beds for inborn neonates; level 2, five beds for 
neonates admitted through ER or other hospitals; 
levels 3 and 4, single beds, for septic neonates 
requiring isolation. Our NICU admissions during the 
study period were from two sources: (i) patients born 
at our hospital and (ii) those admitted through the 
emergency room or directly transferred to NICU 
from local hospitals. The unit’s antibiotic policy  
recommends initial empiric cover of ampicillin + 
gentamycin for neonates born at our institute 
requiring admission in NICU, and cefotaxime + 
amikacin for neonates admitted from the ER and 
other institutes.  
 
Organism Identification 
Acinetobacter spp. were identified by Gram stain 
and colony morphology as well as by setting up 
sulphide-indole-motility test medium, citrate 
utilization test, urea hydrolysis test and triple sugar 
iron agar. API 20NE was set up for cases where the 
above tests were inconclusive. For the determination 
of drug susceptibility, the disk diffusion method was 
used according to Clinical and Laboratory Institute 
(CLSI) guidelines [8], which were used previously 
[9]. Polymyxin disks of 300 units were used for 
susceptibility testing. We were unable to have 
complete subspecies data for Acinetobacter; 
therefore, we are reporting all Acinetobacter as the 
Acinetobacter spp. 
Pan-sensitive Acinetobacter was defined as 
sensitive to all first-line drug classes, while multi-
drug resistant Acinetobacter was resistant to more 
than two of the following five drug classes: 
antipseudomonal cephalosporin, antipseudomonal 
carbapenems, ampicillin - sulbactam, 
fluoroquinolones, and aminoglycosides. “Pan-
resistant Acinetobacter” was defined as resistant to 
all antimicrobials undergoing first-line susceptibility 
testing with therapeutic potential against 
Acinetobacter spp. [5].  
 
Statistical analysis 
The retrieved data was analyzed on SPSS version 
16. Demographic features included age in days, 
weight, gender, year of admission, gestational age, 
antibiotics history, deteriorating signs, site of culture, 
length of hospitalization, and discharge disposition. 
Continuous variables (age, weight, and length of stay 
and discharge disposition) were dealt with mean and 
standard deviation, while categorical variables such 
as gender, poor perfusion (3-5 seconds), metabolic 
acidosis (pH < 7.2), low platelets (< or equal to 
50,000), and duration of culture positivity after 
hospitalization were analyzed by frequency and 
percentage. To identify risk factors associated with 
high mortality in Acinetobacter spp. infection in 
neonates, we compared the discharge disposition, 
dead with alive. We set the level of significance at 
0.05. Univariate analysis was performed, and Chi-
square value, Odds ratios and p-values were 
calculated between independent variables and 
outcome variable individually. A p-value of 0.10 was 
considered significant at the Univariate level and a 
cut-off of 0.10 was taken for the multivariate model. 
Interaction was checked among variables with 
biological plausibility and a p-value of 0.1 was 
considered as having a positive interaction and 
therefore kept in the final model. Finally, a multiple 
regression model was applied for all variables in such  
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a way that the variable with the most significant p-
value was entered first in the final model to calculate 
the adjusted odds ratio.  
 
Ethical approval 
The study was approved by the Ethical Review 
Board (ERB) of Aga Khan University, Karachi 
(1187-Ped/ERC-09). 
 
Results 
During the study period of five years, 122 
cultures from 78 neonates were positive for 
Acinetobacter spp. The majority of patients (62%) 
were males. The maximum number of patients with 
Acinetobacter infection was reported in 2006 (n = 
25), followed by 2004 (n = 18). Eight percent of 
patients were on antibiotics at the time of admission. 
Tracheal cultures (6.7 ± 7 days) were positive earlier 
than blood cultures (7.4 ± 10 days), pinpointing the 
narrow time margin between colonization and 
infection. Antibiotics started at the time of admission 
in NICU, in descending order, were ampicillin (n = 
45, 58%), followed by cephalosporins (n = 28, 35%) 
and carbapenems (n = 5, 6%). More than 95% of our 
cohort required ventilatory support and umbilical 
arterial and venous catheterization. 
Mortality among our Acinetobacter spp. infected 
cohort was 47%, and of these, 70% died within four 
days of culture positivity (table 1). The cohort with 
combined trachea and blood culture positivity for 
Acinetobacter had the highest mortality followed by 
single site culture positivity in tissue/wound, tracheal 
secretions and blood (table 2). Pan-resistance was 
extremely common (table 3). Mortality association 
with other bacterial and/or fungal isolates grown on 
culture was not found.  
Crude and adjusted OR was calculated (table 4). 
We identified weight (< 1 kg), preterm with 
gestational age 28 weeks or less, poor perfusion, low 
platelets, metabolic acidosis and shorter length of 
stay as predictors associated with high mortality in 
our neonatal cohort who developed Acinetobacter 
spp. infection during NICU stay. Twenty-three 
percent (n = 18) of the neonates received Polymyxin 
during the stay (10 ± 5 days), and 33% (n = 6) of 
them were expired (p = 0.17, OR 0.468 (0.155 – 
1.409).  
 
Discussion 
Acinetobacter spp. has the reputation of causing 
outbreaks in intensive care units. Resistances to 
major antimicrobial drugs as well as resistance to 
desiccants and disinfectants are the major factors that 
make it a successful and persistent hospital pathogen 
[5]. Multidrug-resistant Acinetobacter baumannii has 
been reported worldwide and is now recognized as 
one of the most difficult health care-associated 
infections to control and treat. Burn ward and 
intensive care unit (ICU) patients and those with 
central intravenous catheters are the main targets of 
this organism [10,11]. Several outbreaks in ICUs, 
burns units [12-15] and NICUs [10,16-18] have been 
reported previously. We also noticed outbreak 
patterns during our specified study period.  
Von-Dolinger [19] has identified very young 
neonatal age at admission (age < 7 days) as a risk 
factor for Acinetobacter neonatal infection in his 
MDRAB series. Approximately 87% of our study 
cohort admitted in NICU on the first day of life later 
developed Acinetobacter spp. infection.  
Surveillance data illustrates increasing resistance 
trends since 2002 in A. baumannii, with more than 
30% of bacteremic isolates in 2005 being resistant to 
gentamycin and piperacillin/tazobactam and with 
non-bacteremic isolates being even more resistant 
[8]. Carbapenems were previously known to be 
effective against MDRAB but since the emergence of 
pan-resistant Acinetobacter spp. it is even more 
difficult to treat this organism. The Centers for 
Disease Control and Prevention (CDC) reports an 
increasing rate of carbapenems resistant A. 
baumannii from 9% in 1995 to 40% in 2004 [11,20]; 
however; the drug resistance and organism virulence 
is different in different parts of the world. The 
majority of Acinetobacter spp. isolated from our 
patients showed MDRAB and pan-resistant patterns. 
Drug susceptibility testing in our cohort revealed 
resistance to all first-line drugs (Table 3), and as 
colistins were not used in first-line susceptibility 
testing[21], we used the term pan-resistant 
Acinetobacter spp. for the Acinetobacter spp. 
sensitive only to polymyxin. Approximately 70% of 
our blood and tracheal isolates showed pan-resistant 
patterns. This may explain why more than two thirds 
of mortalities were within four days (2 ± 3.6 days) of 
culture positivity. These resistance patterns of 
Acintobacter sp. were also reported from our institute 
but the data was from the adult ICU [9.22].  
Clinical signs associated with deterioration and 
poor outcomes in our study patients were the same as 
those for any severe bacterial sepsis. Huang [23] 
described neonatal manifestations in Acinetobacter 
infection, which are similar to our cohort. Certain 
factors such as prematurity [10,24] and low birth  
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Variables n (%) 
Age (on admission) 
First day of life 
2 – 30 days of life 
2.08 ± 4 Days 
68 (87) 
10 (13) 
Gender 
Males 
 
49 (62) 
Year of admission 
2003 (July – Dec) 
2004 
2005 
2006 
2007 
2008 (Jan – Jun) 
 
5 (6) 
18 (23) 
8 (10) 
25 (32) 
13 (17) 
10 (13) 
Weight (on admission) 
1 Kg or less 
> 1 Kg 
1.77 ± 0.88 Kgs 
20 (26) 
58 (74) 
Gestational age 
Term 
Preterm  
 
19 (23) 
59 (75) 
Gestational age category 
28 Weeks or less 
> 28 Weeks of gestation 
 
23 (39) 
36 (61) 
Antibiotics history 
Yes 
 
6 (8) 
Deteriorating sign 
Poor perfusion 
Low platelets 
Metabolic Acidosis 
 
34 (44) 
25 (32) 
25 (32) 
Days of hospitalization at first  Acinetobacter isolation 
Blood 
Tracheal 
Eye 
Tissue / Body fluids 
Urine 
CSF 
 
7.4 ± 10 days 
6.7 ± 7 days 
10.3 ± 8 days 
21 ± 11 days 
20 days 
33 days 
Discharge disposition 
Recovered 
Died 
 
41 (53) 
37 (47) 
Duration between culture positivity and death 
1 – 3 days 
> 3 days 
2 ± 3.6 Days 
26 (70) 
11 (30) 
Length of hospital stay  20 ± 20 Days 
Table1. Demographic features of study population. 
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  Site Total Number (%) Expired (%) 
Blood 
Trachea 
Blood + Trachea 
Tissue 
Trachea + Eye 
Urine 
Urine + Trachea 
Blood + Tissue + CSF 
Blood + Trachea + Eye 
Eye 
Tissue + Trachea 
35 (44) 
17 (22) 
18 (23) 
2 (3) 
2 (3) 
1 (1) 
1 (1) 
1 (1) 
1 (1) 
1 (1) 
1 (1) 
15 (43) 
8 (47) 
12 (67) 
1 (50) 
0 (--) 
0 (--) 
0 (--) 
0 (--) 
1 (100) 
0 (--) 
0 (--) 
 All cultures 
“n” 
Blood culture (total) 
 
Pan-sensitive 
Pan-Resistant Acinetobacter spp.* 
Multi-Drug Resistant Acinetobacter spp. 
57 
 
13 
38 
6 
 
Tracheal culture 
 
Pan-sensitive 
Pan-Resistant Acinetobacter spp.* 
Multi-Drug Resistant Acinetobacter spp. 
55 
 
1 
42 
12 
 
Tissue / Body fluids culture  
 
Pan-Resistant Acinetobacter spp.* 
Multi-Drug Resistant Acinetobacter spp. 
4 
 
3 
1 
 
Eye culture 
 
Pan-Resistant Acinetobacter spp.* 
Multi-Drug Resistant Acinetobacter spp. 
4 
 
3 
1 
 
Urine culture 
 
Pan-Resistant Acinetobacter spp.* 
 
1 
 
1 
 
CSF culture 
 
Multi-Drug Resistant Acinetobacter spp. 
 
1 
 
1 
 
Table2. Number and site of Acinetobacter spp. isolates. 
 
Table3. Acinetobacter spp. and their sensitivities in neonatal cohort. 
 
*pan-resistant Acinetobacter spp. retains susceptibility to polymyxin. 
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weight (LBW) [22,25,26]were associated with 
increasing risk of Acinetobacter infection, probably 
due to increased likelihood of hospitalization in these 
patients. Prematurity and extremely low birth weight 
(ELBW) were 2.9 and 1.5 times associated with 
mortality in our infected neonatal cohort respectively. 
We were unable to find any significant association 
between Acinetobacter BSI and mortality in our 
study participants as reported earlier by Change et al. 
[27].  
Patients with Acinetobacter colonization often have a 
history of prolonged hospitalization [19] or 
antimicrobial therapy (with antibiotics that have little 
or no activity against Acinetobacter) [11]/ We have 
identified an association of shorter duration of stay 
with higher mortality in MDRAB neonates. This 
observation may be due to higher virulence of 
nosocomial organisms, pan-resistance, lower 
immunity and birth weights of the affected patients. 
More studies are required to verify the association.   
 
Limitations 
There are certain limitations of our study. This 
was a single center study, and may not represent the 
findings at other centers in Pakistan. Furthermore,  
 
 
since this was a retrospective chart review, we 
werenot able to assess all the variables and were 
limited by the completeness of documentation by the 
treating physicians. Because of the constraints of the 
chart review, not all confounding variables could be 
dealt with, but we performed a logistic analysis to 
reduce the impact of these variables to the lowest 
levels possible. This one center study has a limited 
number of patients so results should be generalized 
with caution. We didn’t perform any sub-analysis on 
the basis of Acinetobacter sub-species because of 
unavailability of complete data. The majority of our 
study cohort required ventilatory support along with 
central arterial and venous catheterization so we 
didn’t perform any sub-categorical analysis. Study of 
temporo-spatial (extrinsic, ecologic characteristics) 
factors such as colonization pressure, nurse-to-patient 
ratio, and other ward characteristics were not within 
the scope of this study. 
 
Conclusion 
Pan-resistant Acinetobacter infection is life-
threatening in neonates, particularly in premature and 
LBW babies. Struggling as we are with a neonatal 
mortality rate as high as 54/1000 [28], minimizing 
 
Variables Recovered Expired p – value Crude OR (CI)* Adjusted OR (CI)** 
Age 
preterm 
 
30 
 
29 
 
0.726 
 
1.208 (0.418 – 3.49) 
 
-- 
Gestational age 
28 Weeks or less 
 
7 
 
16 
 
0.011 
 
3.70 (1.306 – 10.486) 
 
2.88 (0.500 – 16.640) 
Gender 
Males 
 
25 
 
24 
 
0.726 
 
1.18 (0.470 – 2.970) 
 
-- 
Weight  
Less than 1 Kg 
 
7 
 
13 
 
0.068 
 
2.63 (0.914 –7.7571) 
 
1.53 (0.239 – 9.800) 
Deteriorating sign 
Poor perfusion 
Low platelets 
Metabolic Acidosis 
 
12 
8 
8 
 
22 
17 
17 
 
0.007 
0.01 
0.01 
 
3.54 (1.385 – 9.072) 
3.50 (1.281 – 9.601) 
3.50 (1.281 – 9.601) 
 
2.45 (0.426 – 14.046) 
1.66 (0.378 – 7.290) 
1.67 (0.317 – 8.832) 
Sites of Acinetobacter 
cultures 
Blood 
Trachea 
 
27 
20 
 
28 
22 
 
0.342 
0.496 
 
1.61 (0.599 – 4.343) 
1.36 (0.559 – 3.322) 
 
-- 
-- 
Length of 
hospitalization 
1 – 7 Days 
>7 days 
 
37 
5 
 
15 
20 
 
<0.001 
 
8.47 (2.717 – 26.409) 
 
13.23 (3.481 – 50.303) 
Table 4. Mortality associated risk factors for neonates with Acinetobacter spp. infection. 
 
*Crude Odds Ratio at Univariate analysis 
**Adjusted OR, for only those variables which were found significant at Univariate analysis (Variables with p-value 0.1 were entered into Multivariate analysis). 
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poor hospital outcomes due to neonatal nosocomial 
infections is imperative. Though lack of standardized 
laboratory resources may make this an under-
reported pathogen in developing country hospitals, 
stringent infection control is the most cost effective 
preventive measure. 
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